Navigation Links
Cell Therapeutics, Inc. Announces Institutional Investors Purchase $30 Million of Preferred Stock and Warrants

SEATTLE, June 30, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. (Nasdaq and MTA:CTIC) (the "Company") today announced that it has entered into an agreement to sell, subject to customary closing conditions, $30 million of shares of its Series 13 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to six institutional investors. Each share of Series 13 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 588 shares of common stock at a conversion price of $1.70 per share of common stock, for a total of approximately 17,647,059 shares of common stock.

In connection with the offering, the investors received warrants to purchase up to 8,820,000 shares of common stock. The warrants have an exercise price of $2.15 per warrant share, for total potential additional proceeds to the Company of approximately $19 million upon exercise of the warrants for cash. The warrants are exercisable beginning six months and one day after the date of issuance and expire five years and one day after the date of issuance.

The Company intends to use the net proceeds from the offering for general corporate purposes, which may include, among other things, paying interest on and/or retiring portions of its outstanding debt, funding research and development, preclinical and clinical trials, the preparation and filing of new drug applications and general working capital. The Company may also use a portion of the net proceeds to fund possible investments in, or acquisitions of, complementary businesses, technologies or products. The Company has recently engaged in limited discussions with third parties regarding such investments or acquisitions, but has no current agreements or commitments with respect to any investment or acquisition.

Shares of the Series 13 Preferred Stock will receive dividends in the same amount as any dividends declared and paid on shares of common stock and have no voting rights on general corporate matters.

The closing of the offering is expected to occur on July 5, 2011, at which time the Company will receive the cash proceeds and deliver the securities.

Rodman & Renshaw, LLC, a wholly-owned subsidiary of Rodman & Renshaw Capital Group, Inc., (Nasdaq: RODM), acted as the exclusive placement agent for the offering.  Trout Capital LLC provided financial advisory services.

A shelf registration statement relating to the shares of Series 13 Preferred Stock and warrants issued in the offering (and the shares of common stock issuable upon conversion of the Series 13 Preferred Stock and exercise of the warrants) has been filed with the Securities and Exchange Commission (the "SEC"). A prospectus supplement under Rule 424 of the Securities Act of 1933, as amended, relating to the offering will be filed with the SEC. Copies of the prospectus supplement and accompanying prospectus may be obtained directly from the Company by contacting the Company at the following address: Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119. This press release does not constitute an offer to sell or a solicitation of an offer to buy the Series 13 Preferred Stock or warrants (or the shares of common stock issuable upon conversion of the Series 13 Preferred Stock and exercise of the warrants). No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading prices of the Company's securities. The risks and uncertainties include the risk that the purchase and sale of the Series 13 Preferred Stock and related warrants might not be consummated, investors might not exercise their warrants, the Company's intentions regarding the use of proceeds, and other risk factors listed or described from time to time in the Company's filings with the SEC, including, without limitation, its most recent filings on Forms 10-K, 10-Q and 8-K. Except as required by law, the Company does not intend to update any of the statements in this press release upon further developments.

Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
F: 206.272.4434

Investors Contact:
Ed Bell
T: 206.282.7100
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
2. Serina Therapeutics, Inc. Closes $9.5 Million Financing Round
3. Cancer Research UK Signs Deal With Centella Therapeutics, Inc. to Launch Clinical Development of Radiotherapy-Enhancing Drug
4. Cell Therapeutics, Inc. Announces Institutional Investors Purchase Approximately $16.0 Million of Preferred Stock and Warrants
5. Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results
6. Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Maintains Target Price of $6.50
7. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
8. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2010 Financial Results on February 16
9. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
10. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®
11. Veteran Pharmaceutical Executives Form New American Therapeutics, Inc.
Post Your Comments:
(Date:10/9/2015)... and CINCINNATI , Oct. 9, 2015 ... two Design Thinking labs with Konica Minolta Medical Imaging ... CFI to utilize Design Thinking to help healthcare providers ... future using a visual roadmap that they can customize ... --> Primary Imaging is the initial procedure, or ...
(Date:10/9/2015)... 9, 2015 India ... --> India along ... announces addition of 3 divalproex sodium market ... for global markets as well as individually for ... with analysis of major players. ...
(Date:10/9/2015)... , Oct. 9, 2015   Lexicon Pharmaceuticals, Inc. ... TELESTAR Phase 3 clinical study of telotristat etiprate has been ... annual symposium to be held from October 15-17, in ... with patients who completed the randomized treatment portion of the ... a poster session. --> --> ...
Breaking Medicine Technology:
... Minn., May 4, 2011 American Medical Systems® ... devices and therapies for male and female pelvic health, ... Ministry of Health, Labor and Welfare (MHLW) to market ... the treatment of Benign Prostatic Hyperplasia (BPH), or enlarged ...
... 4, 2011 The most recent release of Via ... decision support for advance care planning to encourage early ... treatment intent and likely outcomes. Recent ... effect that attention to planning end of life care ...
Cached Medicine Technology:
(Date:10/9/2015)... ... , ... With the FCPX LUT Vibrance pack from Pixel Film Studios, editors ... Lookup Table that contains a mathematical formula for modifying an image. The LUT changes ... with 60 vibrant CUBE LUT files. , Inspired by many YouTube make-up ...
(Date:10/9/2015)... ... 09, 2015 , ... Dentist in Huntington Beach , ... that uses clear, plastic aligners. This alternative to braces has become wildly popular ... patients to complete treatment in privacy. Additionally, Invisalign aligners are removable, so patients ...
(Date:10/9/2015)... Stockton, CA (PRWEB) , ... October 09, 2015 ... ... year anniversary of their “Agents of Change” program, a community improvement initiative that ... The newest charity to benefit from the assistance of Confidence Plus Insurance is ...
(Date:10/9/2015)... ... October 09, 2015 , ... ViewPoint Center, a teen mental health hospital ... mental illness, the stigma associated with mental illness causes many to hide away in ... importance of supporting teens with mental illness , providing teens with comprehensive diagnostic ...
(Date:10/9/2015)... ... , ... Most people assume that Chinese food is more nutritious than American ... T’ai Chi Master and integrative medicine guru Steven Aung, MD agrees with that assessment, ... that they potentially complement one another, with each supplying nutritional elements the other may ...
Breaking Medicine News(10 mins):
... Sales and Marketing Veteran to Drive International Retail Expansion, ... Group and New WrinkleFree Brand Line ExtensionIRVINE, Calif., Jan. ... developer and distributor of medically developed and efficacy-based skin ... mass market retail locations throughout the U.S., announced today ...
... The following statement can be attributed to Michael ... has consistently said two things: We are not ... But we have urged public policy makers to ... merger without conditions, because without conditions the merger ...
... (Nasdaq: OMCL ), a leading provider of system solutions to acute healthcare ... quarter 2008 financial results. , What: Omnicell ... webcast, When: January ... Lipps, chairman, president and chief executive officer, ...
... Maine, Jan. 21 IDEXX Laboratories, Inc. (Nasdaq: ... quarter and full-year financial results for Friday, January 30, at ... conference call beginning at 9:00 a.m. (eastern) on that day. ... through a link on the IDEXX Web site, ...
... can lead to failure, , , WEDNESDAY, Jan. 21 (HealthDay ... a common cause of kidney transplant failure may help ... polyomavirus nephropathy, which affects about 9 percent of kidney ... adults but can cause serious problems for people with ...
... CAMBRIDGE, Mass. -- Schizophrenia may blur the boundary between ... that is involved in self-reflection, and thus causing an ... brain imaging study has found. , The traditional ... and emotions that characterize the disease are caused by ...
Cached Medicine News:
... 4 Dot with 955R Red/Green glasses ... presence of binocular vision. Consists of ... discs: two green, one red and ... any distance. Patient wears red/green glasses ...
20 foot distance 22-1/2" X 11-1/2". This test for illiterate patients has HOTV letters on one side and Allen figures on the other....
Angled 30 degree shaft. 13 mm from tip to bend with 2.5 mm hook curved tip. Polished finished. Overall length excluding hub: 35 mm, 1.4 inches....
McIntyre-Binkhorst, length 18 mm....
Medicine Products: